

The LIT - Leibniz Institute for Immunotherapy (foundation under civil law) (<https://lit.eu>) is a biomedical research center focusing on translational immunology in the fields of cancer immunotherapy, transplant rejection and autoimmunity. The objective of the LIT is to develop innovative and efficient cellular immune therapeutics in these areas. Our own GMP laboratories and close networking with University and University Hospital offer excellent opportunities for clinical translation of novel immune cell products.

The Next-Generation-Sequencing Core Facility (headed by Prof. Dr. Michael Rehli) supports the LIT researchers in high-throughput data generation, processing, analysis, visualization and interpretation, as well as by providing IT infrastructure, software training and consulting services.

We are looking for a highly motivated and experienced

Computational Scientist/ Bioinformatician (m/f/d) **- MR-2024-1**

with enthusiasm for academic research to join our bioinformatics team as a staff scientist. The position is full-time (40.1 hours per week), initially limited as a substitute (parental leave) for 1 year. The position can also be filled part-time.

Job description:

- you will perform bioinformatical and statistical analysis of molecular profiling data including single cell and bulk NGS assays and drive the development and implementation of new technologies.
- develop new bioinformatic workflows and pipelines.
- work together with an interdisciplinary team of bioinformaticians, biologists and physicians.
- support LIT scientists in processing, analysis interpretation and publication of transcriptomic, epigenomic and other high-throughput data.
- improve NGS data analysis algorithms and design novel applications e.g. in the area of single cell sequencing or integration of multi-omic data types.
- you will support researchers by consulting and software training.

Requirements:

- applicants should hold an academic degree (MSc/PhD) in a relevant field (e.g. Bioinformatics Informatics, Computational Biology, Biostatistics, Data Sciences preferably with a background in NGS analysis.
- the applicants should be highly self-motivated and be able to develop and pursue research projects independently as well as in collaborations with multi-disciplinary teams.
- the applicants should be highly self-motivated and be able to develop and pursue research projects independently as well as in collaborations with multi-disciplinary teams.
- experience in statistical data analysis and programming (e.g. R, Python, Perl, C++) as well as workflow management systems (e.g. snakemake, CWL, Nextflow)
- knowledge of standard bioinformatics tools for analyzing and interpreting Next Generation Sequencing data
- proficiency in written and oral command of English

We offer:

- An international cutting-edge research environment that offers exciting and diverse opportunities
- Perspectives for further scientific qualification
- Possibility to visit international conferences and collaborating centers
- Flexible working hours
- Flat hierarchies and short decision-making processes
- A highly motivated and cooperative team
- Job ticket

The remuneration is based on TV-L.

The Leibniz Institute for Immunotherapy targets to increase the share of women in the workforce. Therefore, qualified female candidates are explicitly encouraged to submit their applications. Moreover, the LIT advocates for the compatibility of family and career.

Disabled applicants (m/f/d) with equal qualifications will receive preferential treatment within the recruitment procedure. Please refer to your disability status already in your application.

Please note that expenses that may arise in the context of an eventual job interview cannot be reimbursed.

For more information, please contact Michael Rehli (michael.rehli@ukr.de). We are looking forward to receiving your application including a cover letter, CV, and certificates. Please apply via our homepage <https://rci.hr4you.org/job/view/56> quoting the reference **MR-2024-1**. The application **deadline** is **May 5th, 2024**.